ATE474596T1 - Impfstoff gegen humanes papillomavirus zur oralen verabreichung - Google Patents

Impfstoff gegen humanes papillomavirus zur oralen verabreichung

Info

Publication number
ATE474596T1
ATE474596T1 AT05782348T AT05782348T ATE474596T1 AT E474596 T1 ATE474596 T1 AT E474596T1 AT 05782348 T AT05782348 T AT 05782348T AT 05782348 T AT05782348 T AT 05782348T AT E474596 T1 ATE474596 T1 AT E474596T1
Authority
AT
Austria
Prior art keywords
oral administration
against human
human papillomavirus
vaccine against
papilloma virus
Prior art date
Application number
AT05782348T
Other languages
English (en)
Inventor
Toshiyuki Sasagawa
Hideki Tohda
Yuko Hama
Original Assignee
Asahi Glass Co Ltd
Univ Kanazawa Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd, Univ Kanazawa Nat Univ Corp filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ATE474596T1 publication Critical patent/ATE474596T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05782348T 2004-09-10 2005-09-09 Impfstoff gegen humanes papillomavirus zur oralen verabreichung ATE474596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004263580 2004-09-10
PCT/JP2005/016638 WO2006028214A1 (ja) 2004-09-10 2005-09-09 経口投与ワクチン

Publications (1)

Publication Number Publication Date
ATE474596T1 true ATE474596T1 (de) 2010-08-15

Family

ID=36036496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05782348T ATE474596T1 (de) 2004-09-10 2005-09-09 Impfstoff gegen humanes papillomavirus zur oralen verabreichung

Country Status (11)

Country Link
US (2) US20070154491A1 (de)
EP (1) EP1790332B1 (de)
JP (1) JP4840774B2 (de)
KR (1) KR101187625B1 (de)
CN (1) CN101010099B (de)
AT (1) ATE474596T1 (de)
AU (1) AU2005280896B2 (de)
CA (1) CA2579882C (de)
DE (1) DE602005022458D1 (de)
RU (1) RU2405568C2 (de)
WO (1) WO2006028214A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
DE102008057451A1 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
DE102009044224A1 (de) * 2009-10-09 2011-04-28 PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 Methode zur Produktion von HCV Virus-ähnlichen Partikeln
US8888607B2 (en) * 2010-12-28 2014-11-18 Taylor Made Golf Company, Inc. Fairway wood center of gravity projection
US9707457B2 (en) * 2010-12-28 2017-07-18 Taylor Made Golf Company, Inc. Golf club
CA3134891C (en) 2019-03-29 2024-06-18 Japan Science And Technology Agency Drug delivery composition
CN111529701A (zh) * 2020-05-14 2020-08-14 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) 一种口服后产生新型冠状病毒抗体的制剂及其制备方法
CN119685379A (zh) * 2024-12-19 2025-03-25 中国医学科学院生物医学工程研究所 一种基因工程化海带基的口服粘膜免疫激活型hpv疫苗及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233639T2 (de) 1991-07-19 2007-05-31 Csl Ltd., Parkville Polynukleotidabschnitt des HPV16-Genoms
US6153201A (en) 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US5871742A (en) * 1993-03-31 1999-02-16 Nippon Zeon Co., Ltd Recombinant Avipox virus encoding polypeptide of mycoplasma gallisepticum, and utilized a live vaccine
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
WO1996012801A1 (en) 1994-10-24 1996-05-02 The Texas A & M University System Oral immunization with transgenic plants
WO1999001557A1 (en) 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
WO2000011140A1 (en) * 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
DK1108035T3 (da) 1998-09-04 2007-09-24 Sanofi Pasteur Ltd Behandling af cervixcancer
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신

Also Published As

Publication number Publication date
JPWO2006028214A1 (ja) 2008-05-08
CA2579882C (en) 2012-07-17
CN101010099A (zh) 2007-08-01
US8282936B2 (en) 2012-10-09
US20070154491A1 (en) 2007-07-05
AU2005280896B2 (en) 2010-08-05
KR20070050465A (ko) 2007-05-15
CA2579882A1 (en) 2006-03-16
US20090017063A1 (en) 2009-01-15
RU2007113184A (ru) 2008-10-27
DE602005022458D1 (de) 2010-09-02
EP1790332B1 (de) 2010-07-21
WO2006028214A1 (ja) 2006-03-16
AU2005280896A1 (en) 2006-03-16
EP1790332A1 (de) 2007-05-30
CN101010099B (zh) 2011-11-09
EP1790332A4 (de) 2009-02-18
RU2405568C2 (ru) 2010-12-10
KR101187625B1 (ko) 2012-10-05
JP4840774B2 (ja) 2011-12-21

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
TR201908199T4 (tr) HPV'ye karşı aşılar.
AP1872A (en) Virus-like particles of human papillomavirus.
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
EP1917033A4 (de) Virusähnliche partikel als paramyxovirus-impfstoffe
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EP1270016A4 (de) Aidsvirus-impfstoff unter verwendung eines sendaivirus-vektors
WO2004003143A3 (en) Viruses and virus-like particles for multiple antigen and target display
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
EP2168977A4 (de) Impfstoffantigen zur induzierung eines kreuzreagierenden und neutralisierenden antikörpers gegen einen hochriskanten typ des humanen papillomavirus
BR112015021974A2 (pt) Composição, e, método de indução de uma resposta imune
DE602005022458D1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
ATE380034T1 (de) Neues verfahren zur herstellung von virus- ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
EP1427443A4 (de) Vakzine mit papilloma-virus-e-proteinen, die durch einen viralen vektor abgegeben werden
SE0002498D0 (sv) Papillomavirus vaccine
ATE526035T1 (de) Tollwut-impfstoff
EA200702077A1 (ru) Вакцина
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
Dougan A single-dose, live oral typhoid vaccine: an achievable goal?
WO2002055542A3 (de) Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties